Annual Meeting News

See the latest annual meeting press releases. Read about schedules, agendas, outcomes, and significant decisions. Browse annual meeting announcements for insights from leading companies.

Apr 18, 2025 at 3:24 AM

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France....
Apr 17, 2025 at 12:07 PM

PPG highlights 2024 performance during annual meeting of shareholders

PITTSBURGH--(BUSINESS WIRE)--PPG (NYSE:PPG) today held its annual meeting of shareholders where Tim Knavish, PPG chairman and chief executive officer, highlighted the company’s 2024 performance. PPG achieved full-year 2024 net sales from continuing operations of $15.8 billion, and adjusted EPS increased 6%, supported by PPG’s strong portfolio and driven by sales of PPG’s technology-advantaged products and strong brands. The company delivered record results in several businesses in 2024, includi...
Apr 17, 2025 at 8:30 AM

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) and sent a letter to its fellow Quanterix shareholders in connection with its opposition to the Company’s proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”)...
Apr 17, 2025 at 8:00 AM
Apr 17, 2025 at 8:00 AM

MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, being held April 25 – 30, 2025 in Chicago, IL. AACR poster presentation details are below: MOMA-313 is a potent and selective inhibitor of the Polθ DNA helicase domain for the treatment of HR-deficient tumors Ses...
Turn Your News Into Headlines!
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up